Showing 1031-1040 of 1388 results for "".
- DERM2019 Day 4: Contact Dermatitis, Dermoscopy Bootcamp, and Morehttps://practicaldermatology.com/news/derm2019-day-4-contact-dermatitis-dermoscopy-bootcamp-and-more/2460103/The last day of DERM2019 included a dermoscopy session and several other key presentations from Jennifer Stein, David Cohen, and Gilly Munavalli. Here’s a brief recap from some of those talks! Dermoscopy Bootcamp Presented by Jennifer Stein
- Vehicles, Infectious Disease, and Acne Updates from Day 2 at DERM2019https://practicaldermatology.com/news/vehicles-infectious-disease-and-acne-updates-from-day-2-at-derm2019/2460099/The DERM2019 NP/PA CME Conference continued to delight audiences with esteemed faculty presenters, including those who presented Friday, including April Armstrong, David Cohen, Kara Gooding, Joseph Gorelick, Julie Harper, Jayme Heim, George Keough, Leon Kircik, Kristine Kucera, Gilly Munavalli, T
- Psoriasis, Psoriatic Arthritis, and AD Updates from Day 1 at DERM2019https://practicaldermatology.com/news/psoriasis-psoriatic-arthritis-and-ad-updates-from-day-1-at-derm2019/2460098/The first day of the DERM2019 NP/PA CME Conference kicked off with a bang! Exciting talks and lively panel discussions from April Armstrong, David Cohen, Adam Friedman, Kara Gooding, and Joe Gorelick were the mainstay of the day. Psoriasis Pathogenesis and Treatment T
- Baylor Dermatologist Offers Anti-Aging Advice in Response to FaceApp Crazehttps://practicaldermatology.com/news/baylor-dermatologist-offers-anti-aging-advice-in-response-to-faceapp-craze/2460097/The FaceApp is taking social media by storm as celebrities and social media users across the nation morph their faces to look decades older. While it is currently being used for comedic purposes, you may have patients asking how to keep the app from turning into reality. Rajani Katta, M
- Novartis Offers Free Genetic Testing for Advanced Melanomahttps://practicaldermatology.com/news/novartis-offers-free-genetic-testing-for-advanced-melanoma/2460095/The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF.
- Topical Collagen Powder May Be Effective for Wound Closurehttps://practicaldermatology.com/news/collagen-may-be-effective-for-wound-closure/2460091/Collagen powder is as effective in managing skin biopsy wounds as primary closure with non-absorbable sutures, according to a first-of-its-kind study published in the Journal of Drugs in Dermatology. Researchers investigated the efficacy of topical collagen powder compared
- Proactiv Works to Change the Conversation about Acne with New Initiativeshttps://practicaldermatology.com/news/proactiv-works-to-change-the-conversation-about-acne-with-new-initiatives/2460072/Proactiv is taking on the acne positivity movement with new initiatives aimed to help validate the emotional journey of people with acne and inspire compassion for others. As part of these initiatives, Brand Ambassador Kendall Jenner will continue
- Sonrei Sea Clearly Gel Sunscreens Launchhttps://practicaldermatology.com/news/sonrei-sea-clearly-gel-sunscreens-launch/2460070/A new eco-friendly, gel-based sunscreen line from Sonrei, LLC is now available. “Crafted for every kind,” Sonrei is driven by a commitment of bringing to market a translucent broad-spectrum SPF with environmental principles at the core, the company says. Sonrei Sea Clearly T
- Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Diseasehttps://practicaldermatology.com/news/novartis-new-data-show-cosentyx-has-durable-response-across-psoriatic-disease/2460068/A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, random
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en